Resiquimod

Source: Wikipedia, the free encyclopedia.
Resiquimod
Topical
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
JSmol)
  • CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O
  • InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19) ☒N
  • Key:BXNMTOQRYBFHNZ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Resiquimod (R-848) is a drug that acts as an immune response modifier, and has

opioid growth factor receptor.[9]
On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma.[10]

See also

References

  1. ^ Patents #5, 939, 090 and 6, 365, 166
  2. S2CID 205257237
    .
  3. .
  4. .
  5. .
  6. .
  7. .
  8. .
  9. .
  10. ^ Committee for Orphan Medicinal Products (27 May 2016). "Resiquimod for the treatment of cutaneous T-cell lymphoma" (PDF). Public summary of opinion on orphan designation. European Medicines Agency.